Skip to Content

Join the 'Pulmonary Hypertension' group to help and get support from people like you.

Pulmonary Hypertension News

Related terms: PAH, Pulmonary Arterial Hypertension

AHA: Missouri Woman Puts Health First After AFib Diagnosis

Posted 25 Sep 2018 by

TUESDAY, Sept. 25, 2018 (American Heart Association) – Alice Hinrichs woke up feeling miserable. She was exhausted, nauseated and her left arm hurt. She thought she was sick, so she called her doctor's office for an appointment. Instead, her doctor urged her to go to a hospital in case her symptoms were warnings for a heart attack. There, she was stunned to learn she had several serious health ...

Actelion Receives FDA Approval of Tracleer (bosentan) for Use in Pediatric Patients with Pulmonary Arterial Hypertension

Posted 14 Sep 2017 by

SOUTH SAN FRANCISCO, Calif, September 6, 2017 – Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for Tracleer (bosentan) for use in pediatric patients aged three years and older with idiopathic or congenital pulmonary arterial h ...

Increasing Numbers of Pregnant Women Also Have Heart Disease

Posted 22 May 2017 by

MONDAY, May 22, 2017 – Many more American women with heart disease are choosing to have babies, a new study finds. Researchers looked at more than 81,000 women with heart disease from 2003 to 2012. They found that the proportion who had babies rose 24 percent during that time. "We learned that in addition to the high and growing prevalence of women with heart disease delivering babies, the ...

Pregnancy OK for Most Women With Congenital Heart Conditions: Report

Posted 12 Jan 2017 by

THURSDAY, Jan. 12, 2017 – Women with serious congenital heart defects can usually have successful pregnancies – but they should work closely with their doctors before, during and after pregnancy, according to new recommendations from the American Heart Association (AHA). At one time, women born with complex heart conditions were told they could never have a baby, said Dr. Jamil Aboulhosn, a ...

Uptravi Approved for Chronic Lung Disease

Posted 23 Dec 2015 by

TUESDAY, Dec. 22, 2015 – Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant. PAH is high blood pressure that affects arteries that connect the lungs and heart. It causes the heart to work harder, resulting in shortness of breath and ...

FDA Approves Uptravi (selexipag) for Pulmonary Arterial Hypertension

Posted 23 Dec 2015 by

December 22, 2015 – On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation. “Uptravi offers an additional treatment option for patients with pulmonary arterial hypertension,” said Ellis Ung ...

New Guidelines Focus on Pulmonary Hypertension in Kids

Posted 3 Nov 2015 by

TUESDAY, Nov. 3, 2015 – The first guidelines for diagnosis and treatment of pulmonary hypertension in children have been released by the American Heart Association and the American Thoracic Society. Pulmonary hypertension is a sometimes fatal heart and lung disease that affects nearly two of every 1,000 babies born each year. Children with the condition have blockages in the blood vessels of ...

Exercise Appears Safe, Helpful for Pulmonary Hypertension

Posted 4 Sep 2015 by

FRIDAY, Sept. 4, 2015 – Exercise can be beneficial and safe for people with pulmonary hypertension, researchers report. Pulmonary hypertension is a type of high blood pressure that affects the lungs and heart, causing breathing problems, fatigue and dizziness. Left untreated, it can lead to heart failure, according to background information from the study. "Clinicians have traditionally been ...

Impotence Drug Aids Treatment of Rare Lung Disease: Study

Posted 26 Aug 2015 by

WEDNESDAY, Aug. 26, 2015 – A combination treatment using the erectile dysfunction drug Cialis may greatly reduce death and hospitalization from an incurable lung disease that mainly affects women, a new clinical trial shows. Cialis combined with a blood pressure medication called ambrisentan (Letairis) significantly reduced the progression of pulmonary arterial hypertension, according to results ...

Risk to Baby From Antidepressant Use in Pregnancy Is Small, Study Says

Posted 2 Jun 2015 by

TUESDAY, June 2, 2015 – Babies born to mothers taking antidepressants in late pregnancy may be slightly more likely to develop a rare circulation disorder, a new study suggests. However, the increased risk of the disorder – known as persistent pulmonary hypertension of the newborn (PPHN) – is small, and similar to the risk in women with untreated depression. "Although we cannot exclude the ...

FDA Medwatch Alert: Revatio (sildenafil): Drug Safety Communication - FDA Clarifies Warning About Pediatric Use for Pulmonary Arterial Hypertension

Posted 31 Mar 2014 by

ISSUE: FDA is clarifying its previous recommendation related to prescribing Revatio (sildenafil) for children with pulmonary arterial hypertension (PAH). Revatio is FDA-approved only to treat PAH in adults, not in children; however, health care professionals must consider whether the benefits of treatment with the drug are likely to outweigh its potential risks for each patient. FDA revised the ...

FDA Approves Orenitram (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension

Posted 8 Jan 2014 by

SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ – United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. "This approval marks the first time that the FDA has approved an ...

FDA Approves Opsumit to Treat Pulmonary Arterial Hypertension

Posted 24 Oct 2013 by

October 18, 2013 – The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation. PAH is high blood pressure that occurs in the arteries that connect the heart to the lungs. It causes the right side of the ...

FDA Approves Adempas to Treat Pulmonary Hypertension

Posted 8 Oct 2013 by

October 8, 2013 – The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs. It makes the right side of the heart work harder than normal. In its various forms, pulmonary hypertension is a chronic, progressive, debilitating ...

FDA Medwatch Alert: Revatio (sildenafil): Drug Safety Communication - Recommendation Against Use in Children

Posted 30 Aug 2012 by

ISSUE: FDA notified healthcare professionals and their medical care organizations that Revatio (sildenafil) should not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension (PAH).This recommendation against use is based on a recent long-term clinical pediatric trial showing that: (1) children taking a high dose of Revatio had a higher risk of death than children taking ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Thromboembolic Pulmonary Hypertension, Persistent Pulmonary Hypertension of the Newborn, Pulmonary Heart or Vascular Disease

Related Drug Support Groups

sildenafil, tadalafil, Revatio, isosorbide dinitrate, Adcirca, Uptravi, Opsumit, Veletri, Letairis, view more... Remodulin, ISDN, Adempas, Isordil, Tyvaso, Orenitram, Isochron, Isordil Tembids, IsoDitrate, ambrisentan, Sorbitrate, bosentan, Dilatrate-SR, Isordil Titradose, Flolan, Tracleer, selexipag, macitentan, riociguat, treprostinil, iloprost, epoprostenol, Ventavis